Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2015
>
Glenmark Pharmaceuticals's Bi-Specific Antibody - GBR 1302 To Enter Phase I Trials
Glenmark Pharmaceuticals's Bi-Specific Antibody - GBR 1302 To Enter Phase I Trials
Read also
How AI May Revolutionize the Pharmaceutical Industry
Many companies and businesses have viewed artificial intelligence (AI) as a tool for amplifying efficiency, such as automating simple tasks and making backend projects more efficient.
TSC Alliance Endowment Fund Invests
TSC Alliance Endowment Fund Invests in Aeovian Pharmaceuticals to Advance Development of an mTORC1 Selective Inhibitor for Tuberous Sclerosis Complex
Promising Target Improves Antitumor Response
Promising Target Improves Antitumor Response in Preclinical Models of Pancreatic Cancer
UK approves GSK's twice-yearly asthma drug
Reuters - UK's health regulator on Monday approved GSK's (GSK.L), opens new tab twice-yearly drug for use as an add-on treatment for asthma in patients aged 12 and older, as well as fo...
